Literature DB >> 22486317

Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases.

G Belle-van Meerkerk1, E A van de Graaf, J M Kwakkel-van Erp, D A van Kessel, J-W J Lammers, D H Biesma, H W de Valk.   

Abstract

AIMS: The aims of the study are to investigate the prevalence of diabetes in patients with cystic fibrosis compared with patients without cystic fibrosis, and its impact on the outcome after lung transplantation.
METHODS: Data were reviewed from 77 lung transplantation recipients in our centre between 2001 and 2010; 43 patients had cystic fibrosis and 34 patients had other lung diseases (no cystic fibrosis). To define diabetes, we used the American Diabetes Association definition.
RESULTS: Before lung transplantation, diabetes was diagnosed in 63% of patients with cystic fibrosis and 6% of patients without cystic fibrosis (P<0.001). In both groups, approximately 60% of the patients at risk developed new-onset diabetes after transplantation. The mortality in patients with cystic fibrosis was higher in patients with diabetes diagnosed before lung transplantation compared with those without (44 vs. 6%, P=0.04). Diabetes remained an independent factor in multivariate analyses.
CONCLUSIONS: Diabetes diagnosed before lung transplantation has a negative effect on survival after lung transplantation in patients with cystic fibrosis. Pre-existing diabetes is common in patients with cystic fibrosis, in contrast to patients without cystic fibrosis. Development of new-onset diabetes after transplantation is similar in both groups.
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK.

Entities:  

Mesh:

Year:  2012        PMID: 22486317     DOI: 10.1111/j.1464-5491.2012.03676.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  8 in total

Review 1.  Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment.

Authors:  Jessica L Hwang; Roy E Weiss
Journal:  Diabetes Metab Res Rev       Date:  2014-02       Impact factor: 4.876

Review 2.  Comprehensive Care of the Lung Transplant Patient.

Authors:  Ayodeji Adegunsoye; Mary E Strek; Edward Garrity; Robert Guzy; Remzi Bag
Journal:  Chest       Date:  2016-10-08       Impact factor: 9.410

3.  Potent Anti-Inflammatory, Arylpyrazole-Based Glucocorticoid Receptor Agonists That Do Not Impair Insulin Secretion.

Authors:  Brandon J Kennedy; Ashley M Lato; Alexander R Fisch; Susan J Burke; Justin K Kirkland; Carson W Prevatte; Lee E Dunlap; Russell T Smith; Konstantinos D Vogiatzis; J Jason Collier; Shawn R Campagna
Journal:  ACS Med Chem Lett       Date:  2021-09-15       Impact factor: 4.632

4.  Under Utilization of Pancreas Transplants in Cystic Fibrosis Recipients in the United Network Organ Sharing (UNOS) Data 1987-2014.

Authors:  D J Usatin; E R Perito; A M Posselt; P Rosenthal
Journal:  Am J Transplant       Date:  2016-02-15       Impact factor: 8.086

Review 5.  Post-transplant diabetes mellitus in patients with solid organ transplants.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Endocrinol       Date:  2019-03       Impact factor: 43.330

6.  Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients.

Authors:  Gerdien Belle-van Meerkerk; Pim A de Jong; Harold W de Valk; Tim Neefjes; Frank A Pameijer; Johanna M Kwakkel-van Erp; Ed A van de Graaf
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

7.  Cystic fibrosis related diabetes (CFRD) prognosis.

Authors:  Zahrae Sandouk; Farah Khan; Swapnil Khare; Antoinette Moran
Journal:  J Clin Transl Endocrinol       Date:  2021-11-19

8.  Practical guidelines: lung transplantation in patients with cystic fibrosis.

Authors:  T O Hirche; C Knoop; H Hebestreit; D Shimmin; A Solé; J S Elborn; H Ellemunter; P Aurora; M Hogardt; T O F Wagner
Journal:  Pulm Med       Date:  2014-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.